Author

Jurij Hanzel

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Jurij Hanzel  et al.

CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE
CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE

Jurij Hanzel  et al.

CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB
CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB

Jurij Hanzel  et al.

REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE
REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE

Jurij Hanzel  et al.

Item 1 - 4 / 4
1